The circadian system acts as an anti‑aging firewall by timing repair processes such as DNA repair, autophagy, and mitochondrial quality control. Recent work shows that declining BMAL1 levels and weakened oscillations accelerate hallmarks of aging, while NAD+ loss uncouples the clock from autophagy rhythms【4】. However, most interventions focus on restoring phase or NAD+ levels rather than directly amplifying the transcriptional drive of the core clock complex. We hypothesize that pharmacologically increasing the amplitude of CLOCK:BMAL1‑mediated transcription—without altering period—will re‑synchronize the temporal scheduling of repair pathways, reduce damage accumulation, and extend healthspan in mammals.

Mechanism

Circadian amplitude reflects the peak-to-trough difference in expression of clock‑controlled genes. High amplitude ensures that repair enzymes are expressed in tight, narrow windows, preventing futile cycles of damage and repair that waste energy and increase oxidative stress. We propose that a small‑molecule coactivator that stabilizes the CLOCK:BMAL1 heterodimer or enhances its recruitment of histone acetyltransferases (e.g., p300/CBP) will raise transcriptional amplitude. This should:

• Sharpen the circadian peaks of NAD+ biosynthesis genes (NAMPT), thereby reinforcing the NAD+-SIRT1 feedback loop that stabilizes the clock【2】.
• Increase the trough depth of catabolic genes, allowing deeper autophagic flux during the subjective night when lysosomal activity is naturally high【1】.
• Reduce leaky expression of pro‑inflammatory cytokines by limiting their transcription to specific circadian phases, lowering chronic inflammaging.

Testable Prediction

If amplitude enhancement is causal, then mice treated with a CLOCK:BMAL1 coactivator will show:

1. Higher amplitude of PER2::LUC bioluminescence in suprachiasmatic nucleus and peripheral tissues, measured via longitudinal imaging.
2. Improved alignment of autophagy markers (LC3‑II, p62) with the active phase, assessed by circadian sampling of liver and muscle.
3. Lower accumulation of senescence‑associated β‑galactosidase and mitochondrial ROS compared with vehicle controls.
4. Extended median lifespan and delayed onset of age‑related pathology (cataracts, kyphosis, glucose intolerance).

Experimental Approach

• Compound selection: Identify or design molecules that increase CLOCK:BMAL1 DNA‑binding affinity using a fluorescence polarization screen; validate hits for specificity (no effect on PER/CRY repression).
• In vivo dosing: Administer the lead compound via chow to C57BL/6J mice starting at 12 months of age; include groups receiving NAD+ booster (NR) alone and combined treatment.
• Readouts:
  • Bioluminescence recording from PER2::LUC reporters in explanted tissues to quantify amplitude and period.
  • Quarterly circadian profiling of serum metabolites, liver autophagy flux (via chloroquine chase), and muscle mitochondrial respiration.
  • Annual healthspan assessments (grip strength, treadmill endurance, cognitive maze).
  • Survival analysis until natural death.
• Falsification: If amplitude increases but autophagy timing, senescence markers, or lifespan do not improve, the hypothesis that amplitude per se drives protection is refuted. Conversely, if period changes accompany amplitude shifts without benefit, the effect may be nonspecific.

This hypothesis extends the existing NAD+‑circadian‑autophagy framework by positioning transcriptional amplitude as a lever that couples the clock’s timing mechanism to the magnitude of repair output. Demonstrating that boosting amplitude alone can recapitulate—or surpass—the benefits of NAD+ supplementation would prioritize chronopharmacologic strategies as a central pillar of geroprotection.